Biofrontera Inc.
General ticker "BFRI" information:
- Sector: Health Care
- Industry: Medical - Pharmaceuticals
- Capitalization: $12.2M (TTM average)
Biofrontera Inc. follows the US Stock Market performance with the rate: 42.3%.
Estimated limits based on current volatility of 5.5%: low 0.81$, high 0.90$
Factors to consider:
- Earnings expected soon, date: 2026-11-11 bmo
- Total employees count: 92 (-1.1%) as of 2025
- Top business risk factors: Going concern doubt, Dependence on ameluz success, Supply chain disruptions, Trade tariffs, Market competition
- Price in estimated range
- Earnings for 6 months up through Q2 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [0.62$, 1.72$]
- 2026-12-31 to 2027-12-31 estimated range: [0.54$, 1.53$]
Financial Metrics affecting the BFRI estimates:
- Positive: with PPE of -0.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: Inventory ratio change, % of -11.81 <= -3.92
- Positive: -6.89 < Industry operating cash flow per share per price (median), % of -3.83
- Positive: Investing cash flow per share per price, % of 42.07 > 2.40
- Negative: negative Net income
- Positive: -66.29 < Industry operating profit margin (median), % of -43.01
- Negative: Industry earnings per price (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 6.34 <= 10.61
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term BFRI quotes
Long-term BFRI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $34.07MM | $37.32MM | $41.70MM |
| Operating Expenses | $56.75MM | $54.53MM | $53.05MM |
| Operating Income | $-22.68MM | $-17.21MM | $-11.35MM |
| Non-Operating Income | $2.56MM | $-0.53MM | $0.84MM |
| Interest Expense | $0.47MM | $2.04MM | $0.45MM |
| R&D Expense | $0.08MM | $2.09MM | $3.72MM |
| Income(Loss) | $-20.12MM | $-17.74MM | $-10.51MM |
| Taxes | $0.01MM | $0.02MM | $0.03MM |
| Net Income(Loss)* | $-20.13MM | $-17.76MM | $-10.54MM |
| Stockholders Equity | $4.79MM | $4.43MM | $10.48MM |
| Inventory | $10.91MM | $6.65MM | $1.43MM |
| Assets | $27.93MM | $22.10MM | $28.56MM |
| Operating Cash Flow | $-24.89MM | $-10.27MM | $-13.36MM |
| Capital expenditure | $0.01MM | $0.06MM | $0.00MM |
| Investing Cash Flow | $0.62MM | $-0.00MM | $3.00MM |
| Financing Cash Flow | $8.41MM | $14.84MM | $10.85MM |
| Earnings Per Share** | $-13.02 | $-3.22 | $-1.04 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.